Investigators from several medical centers in Japan were surprised to find that women with myelodysplastic syndrome (MDS) had a survival advantage from a 7-day dosing schedule, but that benefit ...

Due to their potential to differentiate into various cell types of adult tissues, bone marrow-derived human mesenchymal stem cells (hMSC) play an increasing role as a source of cells for regenerative ...

Treatment with the demethylating agent 5-Azacytidine leads to prolonged survival for patients with myelodysplastic syndrome, and the demethylation induces upregulation of cancer-testis antigens.

Please provide your email address to receive an email when new articles are posted on . Treatment with ruxolitinib plus azacytidine yielded encouraging spleen response rates and improvement in bone ...

Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome One hundred ninety ...

A new study has shown that the tumor-inhibiting gene TET2 is silenced in a large fraction of cases of acute lymphoblastic leukemia (ALL) in children. The scientists show that the gene can be ...

Scientists in Germany have discovered that bioavailability and efficacy of the blood cancer drug azacytidine increase when the substance is coupled to a fatty acid. Scientists of the German Cancer ...

A phase II study of mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in patients with myelodysplastic syndrome (MDS). This is an ASCO ...

Researchers have suggested that the existing drug 5-azacytidine may offer hope as a new therapy for treating acute lymphoblastic leukaemia (ALL) in children. Results from a new study, completed at ...

A new study from Linköping University has shown that the tumor-inhibiting gene TET2 is silenced in a large fraction of cases of acute lymphoblastic leukemia (ALL) in children. The scientists show that ...